Zydus boosts companion diagnostics with AI-powered CGM Diasens and GlucoLive launch

Diasens and GlucoLive are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care

Novo Nordisk strikes deal with Hims & Hers, expands access to Ozempic & Wegovy in US

Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms

Neuland to launch commercial peptide facility in Hyderabad as global capacity tightens

The first of four planned modules at the new plant is expected to come online by summer 2026

Relmada’s NDV-01 shows strong 12-month results in hard-to-treat bladder cancer

The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients

FDA grants priority review to Enhertu for high-risk HER2-positive breast cancer

Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population

Roche’s experimental obesity drug shows strong weight-loss results in mid-stage trial

The company announced positive topline data from the Phase II ZUPREME-1 trial

Evogene narrows focus to AI-driven molecule discovery after major strategic overhaul

Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud

Alembic enters US branded market with first sales of Pivya UTI treatment

Pivya is Alembic’s first branded pharmaceutica product in the US and is being marketed through Alembic Therapeutics LLC

Eugia Pharma launches Pomalidomide capsules in US market

PK Healthcare granted accreditation under 6th edition by NABH

The 6th Edition NABH framework places strong emphasis on patient safety protocols, robust clinical governance, risk management systems